Borderline ovarian tumours (BOTs) show intriguing characteristics distinguishing them from other ovarian tumours. The aim of the systematic review was to analyse the spectrum of molecular changes found in BOTs and discuss their significance in the context of the overall therapeutic approach. The systematic review included articles published between 2000 and 2023 in the databases: PubMed, EMBASE, and Cochrane. After a detailed analysis of the available publications, we qualified for the systematic review: 28 publications on proto-oncogenes: BRAF, KRAS, NRAS, ERBB2, and PIK3CA, 20 publications on tumour suppressor genes: BRCA1/2, ARID1A, CHEK2, PTEN, 4 on adhesion molecules: CADM1, 8 on proteins: B-catenin, claudin-1, and 5 on glycoproteins: E-Cadherin. In addition, in the further part of the systematic review, we included eight publications on microsatellite instability and three describing loss of heterozygosity in BOT. Molecular changes found in BOTs can vary on a case-by-case basis, identifying carcinogenic mutations through molecular analysis and developing targeted therapies represent significant advancements in the diagnosis and treatment of ovarian malignancies. Molecular studies have contributed significantly to our understanding of BOT pathogenesis, but substantial research is still required to elucidate the relationship between ovarian neoplasms and extraneous disease, identify accurate prognostic indicators, and develop targeted therapeutic approaches.

Tight junction proteins are essential for sealing the cellular sheets and controlling para-cellular ion flux. Our understanding of the role that tight junction proteins, particularly claudins, play in cellular functions and pathologic conditions is continuously expanding. Particularly, the role of claudin-1 in oncogenesis in multiple locations in the human body is coming to light. This review will shed light on the role of claudin-1 in colon cancer. It will address the mechanisms through which claudin-1 becomes dysregulated in colon cancer. This will provide a platform to address results of claudin-1 expression in the third most common malignant tumour worldwide. Furthermore, it will provide updates about possible use of this biomarker in the surveillance of difficult colon maladies, such as inflammatory bowel disease. The use of claudin-1 as a biomarker of diagnostic and prognostic values will provide Medicine with much needed ammunition in the fight against cancer and will bring about, with added refinements, a new chapter in the era of personalized medicine to tackle this disease and match its destructive course with equally powerful and specifically targeted therapies.

BACKGROUND: The current reports on the association of claudin-1 expression with colorectal cancer (CRC) result were controversial. Thus, we conducted a meta-analysis to assess the correlation between claudin-1 expression and the clinical parameters and assess the prognostic value of claudin-1 in CRC.
METHODS: Systematic searches on PubMed, Embase, Elsevier, CNKI (China National Knowledge Infrastructure), Wanfang data and Cochrane Library prior to August 2016 were performed. The pooled odds ratio (OR) with its 95% confidence interval (95 %CI) was used to assess association between claudin-1 expression and clinical parameters of CRC patients, and to assess association between claudin-1 expression and the prognostic value of CRC patients.
RESULTS: Eight studies with a total of 1146 CRC patients were included. Overall, the pooled results showed that low expression of claudin-1 was associated with TNM III-IV stage of CRC patients (OR: 1.714, 95%CI: 1.215-2.418, P = 0.002). Low expression of claudin-1 was also associated with a poor survival in CRC patients (one year survival rate: OR: 2.112, 95%CI: 1.028-4.339, P = 0.042; three years survival rate: OR: 1.501, 95%CI: 1.030-2.186, P = 0.035; five years survival rate: OR: 1.794, 95%CI: 1.139-2.439, P = 0.000). Whereas, low expression of claudin-1 is not associated with gender (OR: 1.259, 95%CI: 0.957-1.657, P = 0.100), tumors\' differentiation (OR: 1.317, 95%CI: 0.916-1.892, P = 0.137), depth of invasion (OR: 1.016, 95 %CI: 0.701-1.472, P = 0.935) and lymph node metastasis group (OR: 1.286, 95% CI: 0.982-1.684, P = 0.06) of CRC.
CONCLUSIONS: Low expression of claudin-1 is associated with TNM III-IV stage and poor prognosis of CRC patients. Low expression of claudin-1 is not associated with gender, tumors\' differentiation depth of invasion and lymph node involvement of CRC patients.

We describe a plexiform perineurioma, which is an extremely rare variant of soft tissue perineurioma. A 43-year-old Japanese man presented with a painless, well-demarcated, elastic, soft tumor measuring 2.0 × 1.9 cm on the upper lip that had persisted for three years. Microscopically, a plexiform tumor composed of minimally atypical spindle cells with wavy nuclei was located in the lamina propria of the oral mucosa. Tumor cells were concentrically arranged around small vessels and aligned in parallel with delicate collagen fibers on a fibromyxoid background in the hypocellular area. Tumor cells were immunohistochemically positive for EMA, GLUT-1, claudin-1, and CD34 and negative for S-100 protein. The histopathological and immunohistochemical profiles of the excised tumor indicated a diagnosis of plexiform perineurioma. The patient has remained free of recurrence for sixteen months. Intraoral soft tissue perineurioma is rare and two of the four reported plexiform perineuriomas, including that described herein, notably involved the intraoral area. According to previous reports, plexiform perineuriomas largely develop in middle-aged women without a history of type 1 or type 2 neurofibromatosis. The clinical courses of all reported plexiform perineuriomas have been benign.

Perineurioma represents a recently described and relatively rare neoplasm in the spectrum of benign peripheral nerve sheath tumours composed of perineurial cells staining immunohistochemically positive for epithelial membrane antigen (EMA). In addition to intraneural, extraneural and sclerosing perineurioma, rare variants of perineurioma may occur, and their knowledge is important in the differential diagnosis of mesenchymal tumours of different lines of differentiation and clinically more aggressive neoplasms. We present a case of deep-seated reticular perineurioma arising on the upper arm of a 34-year-old female and a case of a dermal plexiform perineurioma arising on the lower lip of a 60-year-old female. The diagnosis was confirmed in both cases immunohistochemically; neoplastic cells stained positively for EMA and for the newly described perineurial markers, claudin-1 and glut-1. The morphological spectrum and the differential diagnosis of perineurial neoplasms of skin and soft tissues are discussed.